GlassScriptPhysician profile
Nelly Cohen
NPI 1780657189
$10,726.61
in general payments reported to CMS, 2019-2025
55 companies · $2,037 in 2025
The $2,037 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,274 · 2020: $1,272 · 2021: $1,395 · 2022: $1,694 · 2023: $1,161 · 2024: $1,895 · 2025: $2,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,031 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,031.25 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $926.28 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $912.15 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $778.89 | 2019-2025 | Jardiance |
| Amgen INC. | $762.41 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $725.41 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $592.94 | 2022-2025 | Rexulti |
| Boston Scientific Corporation | $555.83 | 2020-2025 | 2cm Peripheral Cutting Balloon |
| Gilead Sciences, INC. | $459.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $382.77 | 2019-2023 | Steglatro |
| Novo Nordisk INC | $336.95 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $321.69 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $321.55 | 2020-2022 | |
| Abbott Laboratories | $315.54 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $297.95 | 2019-2025 | |
| Astellas Pharma US INC | $267.15 | 2023-2025 | Veozah |
Show all 52 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelly Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.